Fox Chase Cancer Center | Strategic Alliance Partners

The top 5 OncLive TV videos of the week cover insights in renal cell carcinoma, HER2+ breast cancer, multiple myeloma, and chronic lymphocytic leukemia.

Benjamin Croll, MD, discusses the present and potential future standing of biomarkers in RCC.

Benjamin Croll, MD, discusses research focused on understanding response to systemic therapy in RCC.

A Fox Chase Cancer Center study will evaluate a tumor-informed, whole-genome sequencing–based test to assess recurrence risk in early-stage NSCLC.

Robert A. Winn, MD, has been named the next cancer center director for Fox Chase Cancer Center.

Unlike conventional radiation therapy systems, adaptive radiotherapy creates a new plan for each treatment session, allowing clinicians to deliver larger doses of radiation to tumors more safely.

A ctDNA blood test predicted metastatic risk, but not local recurrence, after bladder-sparing cancer treatment.

Girindra Raval, MD, and Hossein Borghaei, DO, MS, discuss Borghaei’s personal journey into medicine and oncology.

Radiation therapy administered prior to surgery rarely shrinks retroperitoneal tumors in sarcoma according to Fox Chase Cancer Center researchers.

SpotitEarly, an early cancer detection startup that uses AI and trained canines to identify cancer odor signatures in breath samples, today announced a strategic partnership with Fox Chase Cancer Center.

Researchers discovered that the oncogene ERG triggers cancer by reprogramming prostate basal cells.

T-cell redirecting therapies can be safely monitored within the home of patients, limiting hospital visits according to researchers at Fox Chase.

Rashmi Khanal, MD , of Fox Chase Cancer Center discusses how TIL therapy can give patients with aggressive disease more hope for the future.

Effectiveness of prostate cancer drugs potentially tied to ancestry according to new research data.

Fox Chase Cancer Center’s Namrata ‘Neena’ Vijayvergia, MD, an expert in gastrointestinal cancers and rare NETs, was recently recognized by two NET advocacy groups for her contributions to the field.

A new method enhances the ability of artificial intelligence models to detect and diagnose skin cancer in individuals with darker skin.

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

The NAPBC has renewed Fox Chase Cancer Center’s accreditation, making it the sixth consecutive time Fox Chase has been honored with this distinction.

Fox Chase Cancer Center revealed for the first time that cancer cells can evade anti-cancer drugs by entering and surviving within bone marrow fibroblasts.

Genetic testing could help determine differences between rare forms of kidney cancer.

Richard Bleicher, MD, FACS, discusses using a novel method to analyze tumor growth rates.

New research from Fox Chase Cancer Center uncovers mechanisms of breast cancer resistance to CDK4/6 inhibitors and offers innovative treatment strategies.

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene that may play an important role in colon cancer.

In a study recently published by researchers at Fox Chase Cancer Center, patients being treated for retroperitoneal sarcoma at multiple facilities experienced longer delays between diagnosis and treatment.

In a study recently published by researchers at Fox Chase Cancer Center, patients being treated for retroperitoneal sarcoma at multiple facilities experienced longer delays between diagnosis and treatment.

Fox Chase Cancer Center Researcher secures funding to investigate toxicity reduction in bladder cancer treatment.

Fox Chase Cancer Center researcher Adria Hasan honored with scholar-in-training award from American Association for Cancer Research.

Jonathan Chernoff, MD, PhD, Cancer Center Director of Fox Chase Cancer Center, was recently elected to the Association of American Physicians (AAP).

Akina Tamaki, MD, highlights treatment considerations, the therapeutic arsenal, and surgical advancements in head and neck cancer.

Akina Tamaki, MD, highlights treatment considerations, the therapeutic arsenal, and surgical advancements in head and neck cancer.